For Elevance Health and other big insurers, 2024 devolved into something of an annus horribilis over the year’s final weeks. And 2025 holds more challenges but also an opportunity for a rebound.
Indianapolis-based Gate Neurosciences, which is in clinical trials of a medicine to treat depression, plans to acquire California-based biotech startup Boost Neuroscience.
IBJ corrects errors in stories and columns. When those are errors of fact or clarifications of context or tone, we will put those corrections here, with links to the corrected stories.
Syra Health is looking to its new AI-powered app, Syrenity, to help it reach profitability and establish itself as a provider of high-tech mental health services.
The promise of a lighter regulatory environment from the Trump administration, lingering effects of the pandemic and a proliferation of would-be buyers all suggest 2025 will be a year of robust dealmaking.
Purdue University’s new multi-use building planned for the northwest corner of Michigan and West streets in Indianapolis is expected to rise 15 stories and open in 2027.
NCAA President Charlie Baker is banking on the momentum college sports appears to be gaining since preliminary approval of the House settlement, which calls for schools to pay players directly for use of their name, image and likeness.
Leading AI companies including Google and Microsoft predict that a new generation of digital helpers termed “AI agents” will completely change how people interact with computers.
In its new proposal, Nippon Steel offered a 10-year guarantee that it would not reduce production capacity at U.S. Steel’s mills in Pennsylvania, Indiana, Alabama, Texas, California and Arkansas without approval by the Treasury-led review panel.
The firm, which helps employers transition workers to individual health insurance plans, has more than doubled its workforce in the last year and hopes to go on an acquisition spree.
Kroger and Albertsons in 2022 proposed what would be the largest grocery store merger in U.S. history. But the Federal Trade Commission sued earlier this year, seeking to block the $24.6 billion deal.
Vivek Ramaswamy owns about $670 million in shares of Roivant Sciences, which is pursuing studies for three drugs that could land before the FDA during Donald Trump’s second term.
Minority- and women-owned businesses are bracing for the end of affirmative action in federal contracting—and the potential loss of contracts worth at least $70 billion a year.
